Parkinson Disease: Clinical Trials

289 trials for Parkinson Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

211 completed, 31 terminated, 17 recruiting, 15 unknown. 289 Phase 3, 53 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3289Completed 211, Terminated 31, Recruiting 17, Unknown 15, Withdrawn 8, Active not recruiting 4, Not yet recruiting 3
Phase 253Completed 29, Recruiting 7, Unknown 7, Terminated 5, Withdrawn 5

Follow Parkinson Disease: new trials by email Literature Review of Parkinson Disease trials Research Report on Parkinson Disease

Trials (filtered) newest first · largest first

All 289 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.4862027-01-012026-09-17
Effect of Botulinum Toxin on Resting Tremor of the Refractory Upper Limb in Parkinsonians
Injection of Dysport then placebo, Injection of placebo then Dysport - PARKINSON DISEASE (Disorder)
Phase 3Not yet recruitingUniversity Hospital, Toulouse392026-12-012026-11-04
Phase â…˘ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
TJ0113 200mg, TJ0113 400mg, Placebo - Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
Phase 3RecruitingHangzhou PhecdaMed Co., Ltd.3002026-11-052026-11-18
VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
VG081821AC, Placebo - Parkinson Disease (PD)
Phase 2 / Phase 3RecruitingZhejiang Vimgreen Pharmaceuticals, Ltd.1522026-07-172026-09-03
Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations
Safinamide, Placebo - PARKINSON DISEASE (Disorder), Pain
Phase 3RecruitingUniversita di Verona602026-04-282026-08-13
Effect of Repetitive Bihemispheric Anodal Transcranial Direct Current Stimulation on Motor Function of Patients With Parkinson's Disease
Transcranial Direct Current Stimulation - PARKINSON DISEASE (Disorder), Parkinson Disease
Phase 3Not yet recruitingDr. Ram Manohar Lohia Hospital302026-02-012026-02-09
A Study of Buntanetap in Participants With PD
buntanetap/posiphen - Parkinson's Disease (PD), Deep Brain Stimulation
Phase 2 / Phase 3RecruitingAnnovis Bio Inc.5002026-01-092026-10-30
Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach
Atomoxetine, Placebo - Parkinson's Disease (PD), Freezing of Gait
Phase 3RecruitingRadboud University Medical Center602026-01-012026-02-27
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Prasinezumab, Placebo - Parkinson's Disease
Phase 3RecruitingHoffmann-La Roche9002025-11-242026-11-05
Metformin in Parkinson Disease
Levodopa Carbidopa, Metformin - Parkinson Disease
Phase 2 / Phase 3RecruitingTanta University602025-11-102025-11-21
Vinpocetine in Patients With Parkinsonian Disease
Levodopa Carbidopa, Vinpocetine - Parkinson Disease
Phase 2 / Phase 3RecruitingTanta University602025-11-102025-12-10
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
LECIG (levodopa, carbidopa, entacapone intestinal gel), Best oral medication - PARKINSON DISEASE (Disorder)
Phase 3RecruitingUniversity Hospital Tuebingen1502025-10-272026-07-13
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
Placebo, Telmisartan, Terazosin (Hytrin) - Parkinsons Disease (PD)
Phase 3RecruitingUniversity College, London12002025-09-122025-10-03
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
bemdaneprocel, Sham surgery - Parkinsons Disease (PD)
Phase 3RecruitingBlueRock Therapeutics1022025-06-172026-11-02
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
BHV-8000 10mg, BHV-8000 20 mg, Placebo - Parkinson Disease
Phase 2 / Phase 3RecruitingBiohaven Therapeutics Ltd.5502025-05-282026-10-22
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
Aria Sensor - Dysphagia, Parkinson Disease
Phase 3CompletedNorthwestern University592025-04-012026-11-05
Ambroxol to Slow Progression in Parkinson Disease
Ambroxol Hydrochloride (420mg), Placebo - Parkinson Disease
Phase 3RecruitingUniversity College, London3302025-02-252025-05-01
Effect of Metformin as Add-on Therapy in Levodopa Treated Parkinson's Disease Patients
Metformin, placebo - Parkinson Disease
Phase 3Active not recruitingBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh742024-12-292025-07-09
Fexofenadine as Adjuvant Therapy in Parkinson Disease
Levodopa/carbidopa, Fexofenadine - Parkinson Disease
Phase 2 / Phase 3RecruitingTanta University462024-12-102026-01-21
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
HRG2010; Sustained-release Carbidopa/Levodopa administered placebo, Sustained-release Carbidopa/Levodopa; HRG2010 placebo - Parkinson's Disease
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.1652024-11-062026-11-16

Showing 20 of 289. Sign in to see all of them.

Narrower conditions

Dyskinesias (24)  ·  Parkinsonian Disorders (17)  ·  Movement Disorders (7)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Essential Tremor (5)  ·  Nervous System Diseases (5)  ·  Neurodegenerative Diseases (5)  ·  Deglutition Disorders (4)  ·  Dementia (4)  ·  Depression (4)  ·  Dizziness (4)  ·  Hypotension, Orthostatic (4)  ·  Pure Autonomic Failure (4)

Broader conditions

Basal Ganglia Diseases (288)  ·  Synucleinopathies (287)  ·  Brain Diseases (284)  ·  Central Nervous System Diseases (284)  ·  Nervous System Diseases (284)  ·  Neurodegenerative Diseases (284)  ·  Movement Disorders (282)  ·  Parkinsonian Disorders (272)  ·  Pathological Conditions, Signs and Symptoms (43)  ·  Signs and Symptoms (43)  ·  Neurologic Manifestations (38)  ·  Mental Disorders (14)  ·  Autonomic Nervous System Diseases (9)  ·  Cardiovascular Diseases (9)  ·  Vascular Diseases (9)

Interventions

Pramipexole (17)  ·  carbidopa, levodopa drug combination (17)  ·  rasagiline (17)  ·  Levodopa (16)  ·  rotigotine (14)  ·  istradefylline (11)  ·  Apomorphine (10)  ·  safinamide (10)  ·  ropinirole (9)  ·  pardoprunox (6)  ·  Carbidopa (5)  ·  perampanel (5)  ·  2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (4)  ·  Tablets (4)  ·  Amantadine (3)

Sponsors

UCB Pharma (15)  ·  Boehringer Ingelheim (11)  ·  AbbVie (10)  ·  GlaxoSmithKline (9)  ·  Kyowa Kirin Co., Ltd. (8)  ·  Newron Pharmaceuticals SPA (8)  ·  Impax Laboratories, LLC (7)  ·  Solvay Pharmaceuticals (7)  ·  Adamas Pharmaceuticals, Inc. (6)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (6)  ·  Kyowa Kirin, Inc. (5)  ·  Radboud University Medical Center (5)  ·  Merck Sharp & Dohme LLC (4)  ·  Mylan Bertek Pharmaceuticals (4)  ·  Otsuka Pharmaceutical Co., Ltd. (4)

Countries

United States (139)  ·  Germany (60)  ·  Canada (53)  ·  Spain (49)  ·  France (47)  ·  Italy (43)  ·  United Kingdom (42)  ·  Poland (38)  ·  Czechia (28)  ·  Ukraine (25)  ·  Israel (24)  ·  Australia (23)  ·  Austria (23)  ·  China (22)  ·  Hungary (21)

Top investigators

Neil Sussman, MD (4)  ·  Phyllis Salzman, Ph.D. (4)  ·  Will Sullivan (4)  ·  Charles Oh, MD (3)  ·  David Squillacote, M.D. (3)

Results publications

PMID 36602886, PMID 38588457, PMID 19126811, PMID 20519680, PMID 21542016, PMID 23667214, PMID 25185211, PMID 26523919, PMID 26882318, PMID 29532440, PMID 30425824, PMID 33864229, PMID 34024025, PMID 36865634, PMID 38070039, PMID 41045349, PMID 41626017, PMID 42475649, PMID 14718694, PMID 16216957, PMID 16381181, PMID 16943402, PMID 17052655, PMID 17502459, PMID 17509486, PMID 17881719, PMID 17895872, PMID 18175337, PMID 18378947, PMID 18413464, PMID 18538636, PMID 19058133, PMID 19454631, PMID 19776408, PMID 19959398, PMID 20008998, PMID 20582993, PMID 20589868, PMID 20723221, PMID 20830819, PMID 20937936, PMID 21080009, PMID 21322021, PMID 21482191, PMID 21733529, PMID 21790503, PMID 21831297, PMID 21887710, PMID 22170276, PMID 22316635

NIH funding

2019 (8), 2004 (5), 2018 (5), 2009 (4), 2025 (4), 2008 (3), 2016 (3), 2005 (2), 2014 (1), 2015 (1), R01AT000941 (1), U01DC003206 (1), U01NS043128 (1), U01NS050573 (1), U01NS080818 (1)